Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ArcticZymes Technologies ASA ( (DE:B4V) ) has shared an announcement.
ArcticZymes Technologies reported a decline in Q1 2025 revenues to NOK 24.9 million, primarily due to reduced orders from a major OEM customer. Despite this, the company achieved record customer numbers and order volumes, indicating progress in its commercial transformation strategy. The company saw significant growth in its biomanufacturing segment, with a 25% increase in orders and a 21% rise in sales year-on-year. The U.S. market showed strong performance, particularly in the cell and gene therapy segment, and the strategic adoption of SAN HQ enzymes by a new U.S.-based CDMO suggests promising long-term growth opportunities.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes for molecular research, In Vitro Diagnostics (IVD), and biomanufacturing. The company is listed on the Oslo Stock Exchange and is headquartered in Tromsø, Norway.
Average Trading Volume: 73,944
Current Market Cap: NOK863.1M
See more insights into B4V stock on TipRanks’ Stock Analysis page.